Therapy News and Research

RSS

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Community-based model of DOT improves HIV patient survival: Researchers

When applied to HIV care, the community-based model of directly observed therapy has no effect on virologic outcomes, but significantly improves patient survival. This is according to researchers at the Johns Hopkins Bloomberg School of Public Health, in collaboration with colleagues at University of Cape Town, South Africa, who conducted the first randomized controlled trial of patient-nominated treatment-supporters providing partial DOT in resource-limited settings.

11 Jun 2010

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Boston Scientific Corporation today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim World Congress, June 16 – 19 in Nice, France.

11 Jun 2010

Researchers demonstrate efficacy of routine psychotherapeutic treatment for depression

Depression is one of the most common forms of psychiatric disorder. It can occur at any time of life and it may affect children and adolescents as well as the elderly. However, depression can usually be suitably managed with the help of cognitive behavioral therapy. Researchers based at Johannes Gutenberg University Mainz have been able to demonstrate both the efficacy and the extent of the beneficial effect of routine psychotherapeutic treatment for depression.

11 Jun 2010

Sundise to implement Medidata Rave as its EDC and CDM solution

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Traditional Chinese Medicine company Sundise will implement Medidata Rave as its electronic data capture and clinical data management solution. Selected for its ability to offer a broad global reach with local in-country support, Medidata will work with Sundise to conduct its first U.S. trial for its TCM treatment for liver fibrosis and will play a key role in supporting the company's strategy to launch in the U.S.

11 Jun 2010

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery.

11 Jun 2010

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

An emerging arm of molecular biology is introducing a new interpretation of traditional concepts of human disease, explains an article published today in Nature. According to author Dr. Arturas Petronis at the Centre for Addiction and Mental Health, the emerging science of epigenetics is offering new insights at the crossroads of genes and the environment, or nature and nurture. Dr. Petronis is head of the Krembil Family Epigenetics Laboratory at CAMH and an international expert in the field.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the American Society of Clinical Oncology annual meeting.

11 Jun 2010

HL survivors do not receive recommended cancer screening tests: Study

A population-based study of 2,071 Hodgkin lymphoma survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Cancer Research UK scientists have discovered cancer-blocking activity for genes carried on chromosome 21 - an extra copy of which is carried by people with Down's syndrome, reveals research published in Nature.

11 Jun 2010

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Competitive Technologies, Inc. today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology Annual Meeting, cited results of the study.

11 Jun 2010

$Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL$

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics, Inc. today reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri, the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.

11 Jun 2010

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.

11 Jun 2010

Programme on surgical and medical treatment strategies for cancer

The 5th ESU Master class on medical treatment for urological cancer is organised by the European School of Urology (ESU) on 25-27 June 2010 at the Barcel- Hotel Sants in Barcelona, Spain.

11 Jun 2010

Therapy News and Research

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Chiasma successfully completes Phase I clinical study of Octreolin

Community-based model of DOT improves HIV patient survival: Researchers

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Researchers demonstrate efficacy of routine psychotherapeutic treatment for depression

Sundise to implement Medidata Rave as its EDC and CDM solution

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

HL survivors do not receive recommended cancer screening tests: Study

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

CTT's Calmare Pain Therapy Treatment shows promise against CIPN

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

Programme on surgical and medical treatment strategies for cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News